Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Ram’s appointment follows the launch of the CDI India division in October 2021.
However, these won’t be available at the nearest chemist store soon
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
First launches expected in H1 2022
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
Subscribe To Our Newsletter & Stay Updated
